Gemma Gene was awarded "Jiangsu Province Large-scale RNA Synthesis and Gene Therapy Engineering Technology Research Center"

        According to the evaluation results of the "Proposed New Provincial Engineering Technology Research Center in 2020" announced by the Department of Science and Technology of Jiangsu Province, Suzhou Gemma Gene Co., Ltd. (hereinafter referred to as the "Company") was rated as "Large-scale Synthesis of RNA and Gene Therapy in Jiangsu Province" "Engineering Technology Research Center" title

        The Jiangsu Engineering Technology Research Center is a scientific research and development entity mainly based on key scientific research institutions with strong scientific and technological strength in relevant industries or fields in Jiangsu Province, high-tech enterprises above the provincial level, and institutions of higher learning.

        In this project review, a total of 407 companies in Jiangsu Province were selected, of which only more than ten are biomedicine-related companies. The company won the title of this project, which is the full recognition of the company's technical level, R&D innovation, talent team, and independent intellectual property rights by the Jiangsu Provincial Department of Science and Technology.

        According to the company’s development strategy plan, the construction of a provincial engineering technology research center aims to establish a technology platform for large-scale synthesis of GMP-level RNA (siRNA, ASO, miRNA, mRNA, etc.), develop RNA drugs with independent intellectual property rights, and enable the company to reach the domestic market. Leading, internationally advanced technological level promotes the development of domestic RNA medicines, including mRNA vaccines.

        Gemma Gene is committed to becoming a leading domestic RNA drug technology service platform. The company was established in 2003 by a team of returned scholars in Shanghai Zhangjiang High-tech Park. In 2007, Gemma Gene’s headquarters was established in the Biological Industrial Park of Suzhou Industrial Park. The company is a leading enterprise in the field of domestic RNA products, with a complete industrial chain from RNA monomer synthesis and small nucleic acid (siRNA) synthesis to small nucleic acid drug research and development and mRNA drug research and development. The company has all the core technologies of the international advanced level of RNA chemical synthesis: including various RNA monomer and modified monomer synthesis technology, common and modified RNA oligo synthesis technology; in terms of molecular detection, it has a variety of fluorescent dye production and nucleic acid fluorescent labeling. Technology, fluorescent quantitative PCR probe synthesis technology, microRNA/circRNA/lncRNA/mRNA and other fluorescent quantitative detection kits, and fluorescent quantitative PCR detection technology; in terms of molecular biology, it has interference expression plasmid vector construction and synthesis technology, virus vector construction As well as packaging technology, mRNA in vitro synthesis technology, Crispr/Cas9 construction services, etc.; animal services, with multiple platforms such as genetically modified animals, CDX, PDX animals; in addition, the company also has a high-throughput RNA library and drug screening technology platform, which is convenient A large number of scientific researchers and pharmaceutical companies conduct all-round research on genes, disease functions and drug development.

        Innovative drug development, from target identification to obtaining optimized candidate molecules, often takes more than a few years and involves complex processes, including target identification, cell animal model establishment, candidate molecule evaluation, and optimization. Among them, Gemma Gene has a unique RNA drug discovery platform from upstream monomers, RNA bulk drug synthesis, vector construction, packaging, cell high-throughput screening, and humanized animal models, which can integrate drug discovery processes and optimize the development cycle. Gemma Gene hopes to establish long-term partnerships with partners to promote the research and development of RNA drugs.

        Gemma currently has 13,000 square meters of R&D and production sites, including 1,000 square meters of GMP production workshops for Class III diagnostic kits and an RNA drug GMP pilot workshop under construction. Gemma sincerely welcomes the establishment of partnerships with colleagues in pharmaceutical companies, relying on Gemma's RNA characteristic drug research and development platform and RNA bulk drug production base as the industrialization platform for new drug development.

        At present, it has established cooperative relations with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tsinghua University, Fudan University, Jiaotong University, Rutgers University, Australia Deakin University and other domestic and overseas universities and scientific research institutions, many famous biomedical companies and large tertiary hospitals to develop RNA diagnostics Reagents and RNA drugs. The company currently has applied for 95 invention patents, including 3 PCT international patents, applied for 1 US patent, 1 Japanese patent, 1 European patent, and obtained 44 authorized patents. The company's RNA-related products and services are sold at home and abroad. Scientists around the world have published more than 16,000 representative papers using Zimmer's products and services, including important journals such as Science, Cell, Nature biotechnology, Nature genetics, and Nature cell biology. Based on the enterprise spirit of "Integrity, Respect, Cooperation and Innovation", the company sincerely welcomes the broad masses of pharmaceutical companies to establish long-term, extensive and win-win cooperation in the fields of RNA gene function research, new drug research and development, and diagnostic reagents.